In the one U.S. cohort study behind most headlines, gastroparesis was recorded in 9.1 of every 1,000 semaglutide users a year and 3.1 of every 1,000 users of a comparison weight-loss drug, a hazard ratio of 3.67 for GLP-1 medicines as a group, resting on four cases among semaglutide users. A 2025 meta-analysis of 55 placebo-controlled trials looked for gastroparesis and concluded that GLP-1 medicines probably have little or no effect on its risk. Measured directly, the slowing is modest: in five pooled studies the stomach took 36 minutes longer to half-empty a solid meal. All four labels say the medicine is not recommended for people with severe gastroparesis.1,5,6,13
What gastroparesis is
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, defines gastroparesis, also called delayed gastric emptying, as a disorder that slows or stops the movement of food from the stomach to the small intestine. The stomach muscles work poorly or not at all, and the stomach takes too long to empty.9 The American College of Gastroenterology adds two conditions in its 2022 guideline: there must be objective evidence of delayed emptying, and no mechanical obstruction at the outlet of the stomach.10 Symptoms alone do not make the diagnosis.
NIDDK lists these symptoms:9
- feeling full soon after starting a meal;
- feeling full long after eating a meal;
- nausea and vomiting;
- too much bloating or belching;
- pain in the upper abdomen;
- heartburn;
- poor appetite.
The disorder itself is not common. NIDDK puts it at about 10 men and about 40 women of every 100,000 people, while symptoms similar to those of gastroparesis occur in about 1 of every 4 adults in the United States. In most cases doctors cannot find the cause. Diabetes is the most common known one: it can damage the vagus nerve, which controls the muscles of the stomach, and the pacemaker cells in the stomach wall.9
That list of symptoms is nearly the list of common reactions on an Ozempic or Wegovy label: nausea, vomiting, abdominal pain, belching, heartburn and an appetite that is meant to fall. The overlap is the reason the question is hard, and the reason this page separates three things that the headlines run together: a stomach that empties more slowly on the drug, a diagnosis of gastroparesis recorded in a claims database, and gastroparesis that persists after the drug is gone.
How much a GLP-1 slows the stomach
All four labels state it plainly: semaglutide delays gastric emptying, and tirzepatide delays gastric emptying. The Ozempic label describes a delay of early postprandial gastric emptying, calls it minor, and counts it as part of how the drug lowers blood glucose after a meal.1,2,3,4
The size of the delay has been measured. A 2024 systematic review pooled 15 studies of GLP-1 receptor agonists that quantified gastric emptying.6
- Solid meals, by scan. In five studies with 247 participants that used gastric emptying scintigraphy, the mean time for half the meal to leave the stomach was 138.4 minutes on a GLP-1 medicine and 95.0 minutes on placebo. The pooled difference was 36.0 minutes, with a 95% confidence interval of 17.0 to 55.0.
- Liquids, by absorption test. In ten studies with 411 participants that used the acetaminophen absorption test, the delay did not reach statistical significance.
- No clear pattern by drug. The type of GLP-1 medicine, short-acting or long-acting, and the duration of treatment did not change the result.
The authors concluded that a delay of about 36 minutes is quantifiable and of limited magnitude relative to standard fasting periods before procedures.6
The times are means from laboratory test meals in five studies of several GLP-1 medicines. They show the size of the effect; they do not predict a particular meal or person.
Two more measurements bear on whether the slowing lasts.
Semaglutide at the Wegovy dose. A 20-week trial of semaglutide 2.4 mg measured emptying at week 20 by the absorption of paracetamol and found no evidence that the stomach emptied more slowly than on placebo.7 That is a liquid-phase test, the kind that showed no delay in the pooled review.
Tirzepatide. The Zepbound and Mounjaro labels say that the delay is largest after the first dose and that the effect diminishes over time.3,4 The study behind that statement, run by the drug's maker, found that once-weekly tirzepatide delayed emptying after a single dose and that the effect diminished after multiple doses in healthy participants. In participants with type 2 diabetes on an escalating schedule, a residual delay was still observed after multiple doses.8
So the measured effect is real, largest at the start, about half an hour for solids on average, and hard to detect for liquids. None of these studies diagnosed gastroparesis. They measured emptying in people who were mostly well.
The study behind the headlines
The figure most often quoted comes from a research letter in JAMA in October 2023.5 Its design matters for reading it.
- Who. The authors drew on a random sample of 16 million patients from a U.S. health claims database covering 2006 to 2020. They took new users of semaglutide (613 people) or liraglutide (4,144) who had a code for obesity and no code for diabetes or a diabetes drug.
- Compared with whom. New users of bupropion-naltrexone (654), a weight-loss drug unrelated to GLP-1 medicines.
- What counted. The first code for gastroparesis, or the use of a promotility agent. Bowel obstruction, pancreatitis and biliary disease were tracked the same way.
- How long. Median follow-up was 0.6 years for semaglutide and 1.7 years for the other two drugs.
| Per 1,000 person-years (cases) | Semaglutide | Liraglutide | Bupropion-naltrexone | Adjusted hazard ratio, GLP-1 group |
|---|---|---|---|---|
| Gastroparesis | 9.1 (4) | 7.3 (66) | 3.1 (3) | 3.67 (1.15 to 11.90) |
| Bowel obstruction | 0 (0) | 8.1 (73) | 1.7 (2) | 4.22 (1.02 to 17.40) |
| Pancreatitis | 4.6 (2) | 7.9 (71) | 1.0 (1) | 9.09 (1.25 to 66.00) |
| Biliary disease | 11.7 (5) | 18.6 (162) | 12.6 (16) | 1.50 (0.89 to 2.53) |
Sodhi and colleagues, JAMA 2023, Tables 1 and 2. Hazard ratios compare semaglutide and liraglutide users together with bupropion-naltrexone users, with 95% confidence intervals.5
One person followed for one year is one person-year. The bars are crude rates; the hazard ratio in the text is adjusted for age, sex, alcohol use, smoking, hyperlipidemia, recent abdominal surgery and region.
Read as absolute numbers, the result for gastroparesis is about 6 more diagnoses a year for every 1,000 semaglutide users, and about 4 more for every 1,000 liraglutide users, than among users of the comparison drug. The authors themselves call the events rare and say they must still be considered by people weighing the drugs for weight loss.5
Five limits come from the paper itself or follow directly from its tables.
- Few cases. The semaglutide rate rests on 4 cases and the comparison rate on 3. The confidence interval for the hazard ratio runs from 1.15 to 11.90, which is wide.
- Mostly liraglutide. Of 4,757 GLP-1 users, 4,144 took liraglutide, a daily injection. The pooled hazard ratio is largely a liraglutide result.
- Not the Wegovy dose. The data end in June 2020, and the authors note that semaglutide was marketed for weight loss only after the study period. Tirzepatide is not in the study at all.
- A code, not a scan. Gastroparesis was defined by a diagnosis code or a prescription for a promotility drug. The paper does not report emptying tests, or whether the diagnosis was made while the drug was still slowing the stomach.
- No body mass index. The database had none. The authors used a statistical check, the E-value, and concluded that unmeasured differences in body mass index were unlikely to explain the results. They also note that it is uncertain whether every GLP-1 user was taking the drug for weight loss.
In a sensitivity analysis that included patients without diabetes whether or not they had an obesity code, the hazard ratios were smaller and their intervals narrower, and the results kept their statistical significance.5 The letter shows an association in claims data. It was not designed to show how long the recorded gastroparesis lasted or whether it resolved when the drug was stopped, and it reports neither.
What the randomized trials add
The authors of the JAMA letter gave a reason for turning to claims data: randomized trials of these drugs for weight loss were not designed to capture such events, because of small sample sizes and short follow-up.5 Two years later a meta-analysis in Gastroenterology answered that objection by pooling them. It searched five databases for placebo-controlled randomized trials of GLP-1 receptor agonists in people with type 2 diabetes, overweight or obesity, or fatty liver disease, and included those that reported any of 15 serious gut and biliary events. Gastroparesis, intestinal obstruction and paralytic ileus were on the list.13
It found 55 trials with 106,395 participants. The drugs increased the risk of gallstones, with a risk ratio of 1.46 and 2 more cases per 1,000 people, and probably increased the risk of gastroesophageal reflux disease, with a risk ratio of 2.19 and 4 more cases per 1,000. For every other event on the list, gastroparesis among them, the authors concluded that GLP-1 receptor agonists probably have little or no effect on the risk.13
The two kinds of evidence answer slightly different questions. A trial compares the drug with placebo in people chosen and monitored by protocol, and records gastroparesis when an investigator reports it as an adverse event. A claims study counts a diagnosis code or a prescription in ordinary care, among people who were not randomized. The trial result is the stronger test of cause, and the claims result may reflect in part how often symptoms on the drug lead to a diagnosis being written down. We read the meta-analysis as an abstract, so the number of gastroparesis events it pooled is not given here.
What the labels say
The prescribing information for Ozempic, Wegovy, Zepbound and Mounjaro handles the question in four places.1,2,3,4
- A warning. Each label has a section headed "Severe Gastrointestinal Adverse Reactions". It ends with the same sentence on all four: the medicine is not recommended in patients with severe gastroparesis.
- The Medication Guide. The patient leaflets of Ozempic, Zepbound and Mounjaro tell people to let their health care provider know before starting if they have severe problems with their stomach, such as slowed emptying of the stomach (gastroparesis) or problems with digesting food.
- Reports after approval. The lists of reactions reported after approval include ileus and intestinal obstruction on all four labels. The word gastroparesis does not appear in those lists.
- Other medicines by mouth. Because the stomach empties more slowly, each label warns that the absorption of oral medicines taken at the same time may be affected. The Zepbound and Mounjaro labels add that tirzepatide may reduce the efficacy of oral hormonal contraceptives for that reason.
The warning gives the share of people in the trials who had a severe stomach or gut reaction of any kind.
| Medicine | Placebo | On the drug |
|---|---|---|
| Ozempic | 0% | 0.5 mg0.4%1 mg0.8% |
| Wegovy injection, adult weight trials | 0.9% | 4.1% |
| Zepbound | 1% | 5 mg1.7%10 mg2.5%15 mg3.1% |
| Mounjaro | 0.9% | 5 mg1.3%10 mg0.4%15 mg1.2% |
Prescribing information, section 5, "Severe Gastrointestinal Adverse Reactions". The figures cover every kind of gut reaction; none of the labels gives a number for gastroparesis.1,2,3,4
Drug effect or gastroparesis: why it is hard to tell
NIDDK's page on gastroparesis draws a line that helps here. It says certain medicines may delay gastric emptying or affect motility, resulting in symptoms that are similar to those of gastroparesis, and it names narcotic pain medicines, some antidepressants, some anticholinergics, some medicines for overactive bladder, and pramlintide, an injected diabetes medicine. Then it adds: these medicines do not cause gastroparesis.9 The page was last reviewed in January 2018 and does not mention GLP-1 medicines. The 2022 guideline of the American College of Gastroenterology does not mention them either; we searched its full text.10
The distinction NIDDK makes for those other medicines is the open question for this class: a medicine that slows the stomach while it is in the body, against a disorder of the stomach's nerves and muscles that stays. The sources on this page settle parts of it and leave parts open.
| Question | What the sources show |
|---|---|
| Does the drug slow the stomach? | Yes. All four labels say so, and pooled scans show 36 minutes more for half a solid meal. |
| Does the slowing fade with time? | For tirzepatide the label says it diminishes over time. For semaglutide 2.4 mg a liquid-phase test found no delay at week 20. |
| Are gastroparesis diagnoses more frequent among users? | In one claims study, yes: 7.3 to 9.1 against 3.1 per 1,000 person-years. In 55 pooled randomized trials, probably little or no effect. |
| Was emptying tested off the drug in those cases? | Not reported. |
| Does it persist after stopping? | None of the sources on this page measured that. |
Labels, Hiramoto 2024, Friedrichsen 2021, Sodhi 2023, Chiang 2025.1,5,6,7,13
How gastroparesis is diagnosed
Doctors diagnose gastroparesis from the medical history, a physical exam, the symptoms and medical tests, NIDDK says, and part of the work is ruling out other problems that could cause the same symptoms. It describes three tests of how fast the stomach empties.9
- Gastric emptying scan (scintigraphy). You eat a bland meal, such as eggs, that contains a small amount of radioactive material, and a camera tracks it. The scan usually takes about 4 hours.
- Gastric emptying breath test. You eat a meal containing a substance that is absorbed in the intestines and passes into the breath, and samples of breath are collected over about 4 hours.
- Wireless motility capsule. A small swallowed device reports how fast the stomach empties and how fast food moves through the small and large intestine.
The gastroenterology guideline names the scan as the standard test, with a strong recommendation: emptying of a solid meal should be followed for three hours or more. The cut-off it cites for a delay is more than 10% of the meal still in the stomach at 4 hours, after a 255-calorie, 2%-fat egg meal. Upper endoscopy and imaging tests are used to look for other problems, such as a blockage of the stomach, that could be causing the symptoms.9,10
A scan measures emptying on the day it is done. On a medicine that delays emptying, a slow result cannot by itself say whether the stomach or the medicine is responsible. NIDDK tells patients to be sure to tell the doctor about all the prescription medicines, over-the-counter medicines and dietary supplements they take.9 Whether and when to pause a GLP-1 before testing is for the doctor ordering the test; no source here gives a rule.
How long the drug stays after the last dose
If the slowing comes from the drug, it should ease as the drug leaves. The labels give the pace. The level of semaglutide falls by half about every week, and the Ozempic label says it will be present in the circulation for about 5 weeks after the last dose. The Wegovy label says about 5 to 7 weeks after the last dose. Tirzepatide has a half-life of about 5 days on the Mounjaro label and 5 to 6 days on the Zepbound label.1,2,3,4
The curve comes from our model, built on each label's half-life, for a person who had been on a settled weekly dose. It is not a blood test, and it shows the drug level, not the speed of the stomach. It is not advice to stop or delay a dose.
The level of a drug and its effect on the stomach are different things, and no source on this page measured how fast emptying recovers after the last dose. The tirzepatide data point the other way from the usual worry: the delay was largest after the first dose and diminished while people kept taking it.3,8
Surgery, sedation and a slow stomach
The place where slower emptying has a recognized consequence is the operating room. All four labels carry a warning headed "Pulmonary Aspiration During General Anesthesia or Deep Sedation". It says there have been rare reports after approval of pulmonary aspiration in patients on GLP-1 receptor agonists who were having elective surgery or procedures under general anesthesia or deep sedation, and who had residual stomach contents despite reported adherence to the fasting instructions.1,2,3,4
The labels are frank about what is not known. Available data, they say, are insufficient to inform recommendations to reduce this risk, including whether changing the fasting instructions or temporarily stopping the medicine could reduce the incidence of retained stomach contents. The one instruction they give is to patients: tell your health care providers before any planned surgery or procedure that you are taking the medicine.1,2,3,4
The 2024 pooled review was written with this question in mind. Its authors judged the 36-minute delay for solids to be of limited magnitude relative to standard fasting periods before procedures, and found no substantial difference for liquids at the time points relevant to procedures.6 That is an average, and the label's reports concern individuals who had food in the stomach after fasting. The decision about a dose before a procedure belongs to the surgical and anesthesia team, who need to know the medicine, the dose and the date of the last injection.
Eating when the stomach is slow
NIDDK's dietary advice for gastroparesis is the most specific guidance there is for a stomach that empties slowly, whatever the cause. A doctor may recommend that you:9
- eat foods low in fat and low in fiber;
- eat five or six small, nutritious meals a day instead of two or three large ones;
- chew food thoroughly and eat soft, well-cooked foods;
- avoid carbonated drinks and alcohol;
- drink plenty of water or liquids that contain glucose and electrolytes, such as low-fat broths, clear soups, low-fiber fruit and vegetable juices, sports drinks and oral rehydration solutions;
- do some gentle physical activity after a meal, such as taking a walk;
- avoid lying down for 2 hours after a meal;
- take a multivitamin each day.
For moderate to severe symptoms, NIDDK says a doctor may recommend drinking only liquids, or eating well-cooked solid foods processed into very small pieces or a paste in a blender.9 The gastroenterology guideline backs the same idea with a conditional recommendation on low-quality evidence: a small particle diet, to increase the likelihood of symptom relief and enhance emptying.10 The nutrition advisory written for people on GLP-1 therapy says, for the same symptoms on the drug, that vomiting is more likely with large meals and that foods high in protein or fat can further slow the emptying of the stomach.11
Low fiber is the opposite of the advice for constipation on the same medicines, where fiber is the first step. Which one applies depends on which problem a person has, and a prescriber or dietitian is the one to sort out a plan when both are present.
The counter below adds up the fat, fiber and calories of a meal from U.S. Department of Agriculture data, so a large meal and a small one can be compared.12
Log meals and symptoms together and see which meals come before a bad day.
Open the appEach tap adds one portion, and a fourth tap removes the food. NIDDK says low in fat and low in fiber without giving numbers, so the bars show what the meal holds and set no limit. The two example meals are ours.
If you have diabetes
Ozempic is a diabetes medicine, and diabetes complicates every part of this question. It is the most common known cause of gastroparesis, according to NIDDK, through damage to the vagus nerve and to nerve and pacemaker cells in the stomach wall. High blood glucose may further delay the emptying of the stomach, and gastroparesis in turn makes blood glucose harder to control.9 The gastroenterology guideline suggests optimal glucose control in diabetic gastroparesis to reduce the risk of it worsening, as a conditional recommendation on a low level of evidence.10
Three consequences follow for someone taking Ozempic or Mounjaro for diabetes.
- The cohort study does not describe you. It excluded everyone with a code for diabetes or a diabetes drug, to remove the higher baseline risk that diabetes brings.5
- The cause is harder to assign. New symptoms of a slow stomach could come from the medicine, from diabetes itself, or from both.
- Blood glucose is on NIDDK's urgent list. Blood glucose levels that are too high or too low, together with symptoms of gastroparesis, are a reason to seek a doctor's help right away.9
The Ozempic label makes no exception for diabetic gastroparesis: the medicine is not recommended in patients with severe gastroparesis of any cause.1
How gastroparesis is treated
Treatment depends on the cause, NIDDK says, and treating the cause sometimes stops the gastroparesis.9 Beyond eating habits and blood glucose, it lists these medicines.
- Metoclopramide increases the contraction of the muscles in the stomach wall, may improve emptying, and may relieve nausea and vomiting.
- Domperidone acts similarly and is available in the United States only under a special program administered by the Food and Drug Administration.
- Erythromycin also increases stomach muscle contraction and may improve emptying.
- Antiemetics help relieve nausea and vomiting. They do not improve emptying.
The guideline says the same of antiemetics: suggested for symptom control, without effect on emptying. It adds that medicines to speed emptying should be considered for gastroparesis of unknown cause and of diabetes, weighing benefits and risks.10 When the slowing comes from a medicine, the prescriber's first question is the medicine itself. The labels allow a slower escalation or a lower maintenance dose for people who do not tolerate a dose, and stopping is a decision to make with the prescriber and not alone.2,3
When to call a doctor
NIDDK says to seek a doctor's help right away for any of the following:9
- severe pain or cramping in the abdomen;
- blood glucose levels that are too high or too low;
- red blood in the vomit, or vomit that looks like coffee grounds;
- sudden, sharp stomach pain that does not go away;
- vomiting for more than an hour;
- feeling extremely weak or fainting;
- difficulty breathing;
- fever.
It also says to seek a doctor's help for signs of dehydration, such as extreme thirst, urinating less than usual and dark-colored urine, and for signs of malnutrition, such as feeling tired or weak all the time and losing weight without trying.9 Weight loss is intended on these medicines, which makes that last sign harder to read and worth raising with the prescriber when it comes with vomiting or an inability to eat.
The lists are NIDDK's for gastroparesis. They cannot examine you. If something feels seriously wrong, do not wait for a page to agree.
Short answers to common questions
Does Ozempic cause gastroparesis?
It slows stomach emptying, which the label states. One claims study found more gastroparesis diagnoses among GLP-1 users, 7.3 to 9.1 per 1,000 person-years against 3.1 on a comparison drug. A meta-analysis of 55 randomized trials found probably little or no effect on the risk.
What is Ozempic stomach paralysis?
It is a popular name for gastroparesis, a disorder in which the stomach takes too long to empty without any blockage.
How common is it?
Rare, in the words of the study's authors. Their figures work out to about 6 more diagnoses a year for every 1,000 semaglutide users than on the comparison drug, based on four cases.
How much does Ozempic slow the stomach?
In pooled scans of several GLP-1 medicines, half a solid meal left the stomach in 138 minutes against 95 on placebo. Liquid-phase tests found no clear delay.
Is it permanent?
None of the sources on this page measured that. Semaglutide stays in the circulation for about 5 weeks after the last dose, so the drug is still present for weeks after stopping.
Does Zepbound or Mounjaro do the same?
Tirzepatide also delays gastric emptying. Its labels say the delay is largest after the first dose and diminishes over time. It was not in the claims study.
Can I take a GLP-1 if I already have gastroparesis?
All four labels say the medicine is not recommended in patients with severe gastroparesis. The Medication Guides say to tell the provider about slowed stomach emptying before starting.
Should I stop before surgery?
The labels say the data are insufficient to recommend for or against it. They tell patients to inform their providers before any planned surgery or procedure.
How is gastroparesis diagnosed?
By a test that measures emptying, usually a 4-hour scan after a standard meal, once a blockage has been ruled out. More than 10% of the meal left at 4 hours is the usual cut-off.
How this page was built
Every number was read in its source on November 20, 2026. The label statements come from the current prescribing information of the four medicines. The incidence figures come from the full text of the 2023 JAMA research letter, and the trial evidence from the abstract of a 2025 meta-analysis. The emptying times come from the abstract of a 2024 meta-analysis and from a tirzepatide study by the drug's maker, both read as abstracts, and from a 20-week semaglutide trial funded by its maker. The definition, diagnosis, diet and warning signs come from five NIDDK pages last reviewed in January 2018 and from the full text of the 2022 American College of Gastroenterology guideline.
The limits are these. The claims study is observational, small for semaglutide, ends in 2020 and does not include tirzepatide, and the meta-analysis of trials was read as an abstract. No source here followed people after stopping the drug. The NIDDK pages and the guideline predate the wide use of these medicines for weight loss and do not mention them. The level curve is a model of the drug in the blood and says nothing about how fast a particular stomach empties. This page does not suggest doses or advise stopping a medicine.
Sources
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 12 and 17. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7 and 12. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 2023;330:1795-1797. doi:10.1001/jama.2023.19574
- Hiramoto B, McCarty TR, Lodhia NA, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol 2024;119:1126-1140. doi:10.14309/ajg.0000000000002820
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280
- Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 2020;22:1886-1891. doi:10.1111/dom.14110
- National Institute of Diabetes and Digestive and Kidney Diseases. Gastroparesis: Definition and Facts; Symptoms and Causes; Diagnosis; Treatment; Eating, Diet, and Nutrition. Last reviewed January 2018, read November 20, 2026. niddk.nih.gov
- Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol 2022;117:1197-1220. doi:10.14309/ajg.0000000000001874
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
- U.S. Department of Agriculture, Agricultural Research Service. FoodData Central, SR Legacy (2018), read November 20, 2026; the entries for the 24 foods in the meal counter. fdc.nal.usda.gov
- Chiang CH, Jaroenlapnopparat A, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-1281. doi:10.1053/j.gastro.2025.06.003
Related analyses
Ozempic side effects: how common each one is by dose, and when they ease
Wegovy side effects: how common each one is, when it peaks and how long it lasts
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Zepbound and birth control pills: the 4-week rule, with your dates
Log each dose and each symptom, and bring the dates to your prescriber.
Open Dose Insider